Rasha Aboelhassan shared on LinkedIn:
“Myriam Chalabi. Kok Haw Jonathan Lim. YO boxing session.
Should we try immunotherapy for all patients?
No. We should follow guidelines and it’s only dependant on patients profiles
I have another question:
Do your patient accept the long life possible side effects if he is going to have adequate survival benefit?”
Source: Rasha Aboelhassan/LinkedIn
More posts featuring Rasha Aboelhassan on oncodaily.com
Rasha Aboelhassan is a Senior Oncology Consultant at Nasser Institute Hospital. In addition to her clinical role, she volunteers as a reviewer for the World Journal of Surgical Oncology, contributing to advancements in the field and is in the Editorial Staff of Egyptian Journal of Human Genetics.
